Hallmark Barcelona Science Park innovation Blog Post

2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are…

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2 Blog Post

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.

 

 

SOM Biotech appoints Alain Duguet PhD as Head of Chemical Manufacturing and Control Blog Post

The biotech company SOM Biotech, based in the Barcelona Science Park and specialized in drug development and discovery, has named Alain Duguet as the new head of Chemical Manufacturing and Control. Duguet is an accredited consultant and expert in the definition, management, evaluation and optimization of the production processes of medicines for the pharmaceutical industry. He has worked in the pharmaceutical industry for over three decades for large multinationals, including Sanofi, where he led this area for over 15 years.

 

SOM Biotech announces the in vitro confirmation of three drug candidates for COVID-19 with the Ewha Womans University Blog Post

SOM Biotech, a clinical-stage drug discovery and development company based in the Barcelona Science Park, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19 in collaboration with the Ewha Womans University in South Korea. A patent application has been filed to provide method of use protection for the three compounds worldwide. All three drugs can be repurposed to treat COVID-19 and the company is working on the fastest way to prove them in patients.

 

SOM Biotech closes a €2M financing round Blog Post

SOM Biotech –a clinical-stage biopharmaceutical company specialized in drug repositioning to treat rare diseases of the nervous system – has just closed a €2M financing round. The company, based at the Barcelona Scientific Park, will allocate this capital to boost its activities of internalization, co-development and licensing, as well as to finance a phase II trial of a drug for Huntington’s disease, the second program of the company that reaches clinical stages.